Sage Therapeutics, Inc.
SAGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $330 | $1,297 | $2,262 | $2,496 |
| - Cash | $81 | $71 | $163 | $294 |
| + Debt | $12 | $5 | $12 | $18 |
| Enterprise Value | $261 | $1,231 | $2,111 | $2,220 |
| Revenue | $41 | $86 | $8 | $6 |
| % Growth | -52.3% | 1,024.8% | 21.8% | – |
| Gross Profit | $32 | $84 | $7 | $6 |
| % Margin | 77.1% | 97.5% | 89.4% | 91.2% |
| EBITDA | -$409 | -$545 | -$546 | -$457 |
| % Margin | -992.9% | -630.5% | -7,102.1% | -7,240.4% |
| Net Income | -$401 | -$541 | -$503 | -$451 |
| % Margin | -971.5% | -626.3% | -6,547.8% | -7,146.9% |
| EPS Diluted | -6.59 | -9.05 | -8.49 | -7.68 |
| % Growth | 27.2% | -6.6% | -10.5% | – |
| Operating Cash Flow | -$267 | -$541 | -$460 | -$378 |
| Capital Expenditures | $0 | -$1 | -$1 | -$0 |
| Free Cash Flow | -$267 | -$541 | -$461 | -$379 |